The U.S. FDA late Friday approved BridgeBio Pharma’s (NASDAQ:BBIO) lead asset Attruby for the rare heart disorder transthyretin cardiac amyloidosisin in a potential setback to Pfizer (NYSE:PFE), which already markets Vyndaqel, a rival therapy for the disease.
